NEW YORK (GenomeWeb News) - Genizon Biosciences and pharmaceutical giant Pfizer have reached a licensing and collaboration agreement that gives Pfizer diagnostic rights to Genizon's research programs in Alzheimer's, attention deficit hyperactivity disorder, and endometriosis.
 
Pfizer has agreed to pay Genizon upfront license fees and will also fund the company’s research on genetic variations associated with those diseases. Pfizer will also buy an equity stake in the company, subject to certain closing conditions.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

ScienceInsider reports that a new security policy at the US Food and Drug Administration may prevent foreign nationals from working there.

WBUR in Boston looks into Orig3n's genetic fitness assessments to find more research is needed.

Cleveland.com reports that getting a DNA profile removed from a law enforcement database can be tricky.

In PNAS this week: de novo mutations contribute to non-syndromic craniosynostosis, fungal tree of life, and more.